- In February 2023, the European Medicines Agency (EMA) issued guidelines aimed at improving the clinical development of therapies for rare endocrine disorders, including Addison’s disease. These included considerations for innovative delivery routes and long-acting corticosteroids.
- The industry is witnessing a growing trend toward the development of personalized hormone replacement therapies, emphasis on adrenal-specific biomarkers, and increased use of digital platforms for patient monitoring. Additionally, there is a strong focus on improving drug adherence and reducing side effects through modified-release and dual-release formulations.
Frequently Asked Questions
Asia-Pacific is the fastest growing region due to rising patient awareness, increasing access to specialized treatments, and rapid expansion of healthcare infrastructure.
The emergence of long-acting corticosteroids, expansion of biologics, and adoption of suprachoroidal delivery technologies are shaping future trends.
Key drivers include rising prevalence of autoimmune and infectious diseases, increasing awareness of uveitis, and growing demand for targeted and personalized therapies.
Challenges include side effects associated with long-term corticosteroid use, limited availability of biologics in low-income regions, and diagnostic complexities in early-stage uveitis.
Biologics segment dominates the market due to their targeted mechanisms, reduced relapse rates, and effectiveness in treating chronic, non-infectious uveitis
